Inhibikase Q2 Loss Widens to $19.6M as Phase 3 PAH Trial Costs Surge; $50M ATM Sale to RA Capital Closed in July
IKT sits 84% above its 52-week low of $1.33.
Summary
Inhibikase reported a Q2 net loss of $19.6M as Phase 3 PAH trial costs surged, then disclosed a $50M ATM stock sale to RA Capital in July to bolster its $159M cash position.
Key Events · Earnings and Guidance · IKT
-
Q2 Loss Doubles on Trial Costs
Net loss widened to $19.6M ($0.11/share) from $9.9M a year ago, as R&D expenses surged 154% to $13.4M for the Phase 3 IMPROVE-PAH study.
-
$50M ATM Sale to RA Capital
In July 2026, the company sold 25M shares to RA Capital Management for $50M gross proceeds, with 18.03M shares later exchanged for pre-funded warrants — adding significant dilution.
-
Cash Runway Extended but Burn Accelerating
Cash, equivalents, and marketable securities stood at $159M at June 30, 2026; the July ATM sale adds $50M, but the quarterly cash burn rate is rising as the trial expands.
-
BIOSECURE Act Risk Disclosed
A new risk factor highlights reliance on a WuXi AppTec subsidiary for manufacturing; if WuXi is designated a 'biotechnology company of concern,' the company may need to find alternative suppliers.
Analysis · IKT · Life Sciences
Inhibikase's Q2 2026 loss nearly doubled year-over-year to $19.6 million, driven by a 154% jump in R&D spending as the pivotal IMPROVE-PAH Phase 3 trial ramps up globally. The company ended June with $159 million in cash and securities, then raised an additional $50 million in July by selling 25 million shares to RA Capital Management through its ATM facility — a move that extends runway but adds dilution. The filing also discloses a new risk factor around the BIOSECURE Act and its reliance on a WuXi AppTec subsidiary for manufacturing, which could force a costly supply chain transition. While the cash position is strong, the accelerating burn rate and the need for a large ATM sale just after quarter-end signal that the Phase 3 trial is consuming capital faster than some may have expected.
At the time of this filing, IKT was trading at $2.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $323.5M. The 52-week trading range was $1.33 to $2.53. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.